Shuttle Pharmaceuticals Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital and Steven Boyd have reduced their beneficial ownership in Shuttle Pharmaceuticals Holdings, Inc. to 4.99% of common stock.
NASDAQ
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Shuttle Pharmaceuticals Holdings
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 9.99% in Shuttle Pharmaceuticals Holdings, Inc.'s common stock as of March 31, 2025.
NASDAQ
SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 7.51% Stake in Shuttle Pharmaceuticals Holdings
Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 7.51% in Shuttle Pharmaceuticals Holdings, Inc., totaling 306,057 shares of common stock as of December 31, 2024.